Sweet's syndrome secondary to granulocyte colony-stimulating factor

Prevost‐Blank, Paula L.; Shwayder, Tor

doi:10.1016/s0190-9622(96)90132-2

Cited by 46 publications

(29 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…95 SS can be idiopathic, parainflammatory, paraneoplastic, associated with pregnancy, 95 and drug induced. 102 The incidence of SS in IBD is much rarer than that of PG; to date, about 40 cases of SS have been reported in association with IBD. SS seems to be predominant in patients with CD rather than in those with UC, the rate of association being about 70% and 30%, respectively.…”

Section: Sweet's Syndromementioning

confidence: 99%

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Marzano

Borghi

Stadnicki

et al. 2014

Inflammatory Bowel Diseases

120

View full text Add to dashboard Cite

The skin is one of the most common extraintestinal organ system affected in patients with inflammatory bowel disease (IBD), including both Crohn's disease and ulcerative colitis. The skin manifestations associated with IBD are polymorphic and can be classified into 4 categories according to their pathophysiology: (1) specific, (2) reactive, (3) associated, and (4) induced by IBD treatment. Cutaneous manifestations are regarded as specific if they share with IBD the same granulomatous histopathological pattern: perianal or metastatic Crohn's disease (commonly presenting with abscesses, fistulas or hidradenitis suppurativa-like features) is the prototype of this setting. Reactive cutaneous manifestations are different from IBD in the histopathology but have close physiopathological links: pyoderma gangrenosum, a neutrophil-mediated autoinflammatory skin disease typically manifesting as painful ulcers, is the paradigm of this group. Among the cutaneous diseases associated with IBD, the most commonly seen are erythema nodosum, a form of panniculitis most commonly involving bilateral pretibial areas, and psoriasis, a T helper 1/T helper 17-mediated erythematous squamous inflammatory disease. Finally, the number of cutaneous adverse reactions because of IBD therapies is progressively increasing. The most frequent drug-induced cutaneous manifestations are psoriasis-like, eczema-like, and lichenoid eruptions, as well as cutaneous lupus erythematosus for biologics, and nonmelanoma skin cancer, mainly basal cell and squamous cell carcinomas for thiopurines.

show abstract

Section: Sweet's Syndromementioning

confidence: 99%

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Marzano

Borghi

Stadnicki

et al. 2014

Inflammatory Bowel Diseases

120

View full text Add to dashboard Cite

show abstract

“…Some authors also include a fifth drug induced variant 10. Most of the patients fall under classical/idiopathic subgroup (75%), followed by parainflammatory (15–16%), paraneoplastic (10–20%), drug-induced (5%) and pregnancy-associated (2%) group 1 9.…”

Section: Discussionmentioning

confidence: 99%

Sweet's syndrome as the presenting manifestation of gall bladder adenocarcinoma

et al. 2012

View full text Add to dashboard Cite

Sweet's syndrome is a neutrophilic inflammatory dermatosis presenting with sudden onset tender red to purple papules and nodules, fever and neutrophilia. Gastrointestinal and urinary tract infections, pregnancy, inflammatory bowel disease, drugs and malignancy are some of the known aetiological factors. Paraneoplastic Sweet's syndrome accounts for 15–20% cases and thus forms an important subset. At times its onset helps in suspecting an underlying malignancy, thus making timely intervention possible. In the present case report Sweet's syndrome was the presenting feature of gall bladder adenocarcinoma; an association that has been rarely reported before.

show abstract

“…13 Similarly, there are many reports of paraneoplastic leukemoid reactions resulting from endogenous secretion of G-CSF by a variety of solid tumors. 14,15 Lesions of SS have certainly been reported in association with exogenous growth factor use, 16 and Requena et al 8 correctly report a recent study that verified elevated levels of endogenous G-CSF in patients with conventional SS. 17 Requena et al 8 were unable to attribute any of their patients' lesions to the use of this growth factor.…”

Section: See Also Pages 834 881 and 887mentioning

confidence: 99%